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Abstract 
Retinoic acid (RA) is a potent teratogen in all vertebrates when tight homeostatic 
controls on its endogenous dose, location or timing are perturbed during early embryogenesis. 
STRA6 encodes an integral cell membrane protein that favors RA uptake from soluble retinol-
binding protein; its transcription is directly regulated by RA levels. Molecular analysis of 
STRA6 was undertaken in two consanguineous human fetuses we previously described with the 
Matthew-Wood syndrome [MIM 601186] in a context of severe microphthalmia, pulmonary 
agenesis, bilateral diaphragmatic eventration, duodenal stenosis, pancreatic malformations and 
intrauterine growth retardation. The fetuses had either a homozygous insertion/deletion in exon 
2 or a homozygous insertion in exon 7, respectively, predicting a premature stop codon in 
STRA6 transcripts. Five other fetuses presenting at least one of the two major signs of clinical 
anophthalmia or pulmonary hypoplasia with at least one of the two associated signs of 
diaphragmatic closure defect or cardiopathy had no STRA6 mutations. These findings suggest a 
molecular basis for the prenatal manifestations of Matthew-Wood syndrome and that 
phenotypic overlap with other associations may be due to genetic heterogeneity of elements 
common to the RA and fibroblast growth factor signaling cascades. 
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Microphthalmia refers to a clinical spectrum that is characterized by a congenital 
reduction in the size of the optic globe(s), which may be reduced to a vestige only visible on 
histological analysis. This most severe form of microphthalmia is sometimes called secondary 
or clinical anophthalmia, and occurs later in development than primary anophthalmia, due to a 
lack of optic vesicle formation from the embryonic prosencephalon. Isolated severe 
microphthalmia/anophthalmia demonstrates both genetic and phenotypic heterogeneity in 
humans, currently implicating genes coding for transcription factors. CHX10 mutations lead to 
microphthalmia, coloboma and cataracts 1, 2; mutations in the RAX gene have been identified in 
an individual with unilateral anophthalmia and sclerocornea in the other eye 3. PAX6 mutations 
lead to diverse congenital ocular malformations, the most common of which is aniridia, but a 
few genotypes have been described to date that engender primary anopthalmia 4 or 
microphthalmia 5-7, as documented in the PAX6 Allelic Variant Database. 
Syndromic microphthalmias can be associated with craniofacial dysmorphic features, 
heart and vascular malformations, skeletal and limb anomalies, skin or gut defects, mental 
retardation and hydrocephalus or combinations thereof [MIM 164180, 206900, 206920, 
248450, 300166, 301590, 309801, 600776, 605856, 607932, 610125, 610126, 601349]. 
Although rare, the association of severe microphthalmia and pulmonary hypoplasia [MIM 
601186] is a distinct entity known as Matthew-Wood syndrome 8. Most authors have reported 
further associations of MWS with cardiac and/or diaphragmatic malformations and intrauterine 
growth retardation (IUGR) 9-13. 
We have excluded mutations in genes encoding the fibroblast growth factor FGF10 and 
its receptor FGFR2IIIb respectively in two familial cases of MWS 14. These proteins are 
essential for the development of all affected organs in MWS 15-17. Meanwhile, STRA6 gene 
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mutations were recently implicated in heterogeneous postnatal associations of clinical 
anophthalmia, pulmonary hypoplasia, diaphragmatic hernia, and cardiac defects 18. A 
molecular analysis of the STRA6 gene was undertaken in the two MWS families we had 
described as well as in five other fetuses presenting at least one of the two major signs of 
clinical anophthalmia or pulmonary hypoplasia and at least one of the two associated signs of 
diaphragmatic closure defect or cardiopathy. 
In all seven fetuses examined, the presence of severe malformations was noted on 
ultrasound examination and after genetic counseling, pregnancies were interrupted. Clinical 
data are summarized in Table 1. Chromosome and molecular analyses and pathological 
examinations were carried out in all cases with full parental consent. Genomic DNA was 
extracted from frozen tissue in fetal cases and from peripheral blood samples for parents 
according to standard protocols.  
Polymorphic markers D15S188, D15S160, D15S991, D15S114, flanking the STRA6 
gene, were chosen using the UCSC Genome Browser and examined in fetal cases 1 and 2 
(Figure 1). The parents of case 1 are a consanguineous couple of Romanian origin, and the 
parents of case 2 are a consanguineous couple of Portuguese origin 14. Homozygous haplotypes 
were demonstrated in each fetus, while the clinically unaffected parents of case 1 had a 
heterozygous haplotype with an allele presumably inherited from a common ancestor (DNA 
was unavailable from the other family members of case 2).  
Primers were subsequently designed to cover the 20 exons and exon-intron junctions of 
the STRA6 gene (NM_022369), including exon 1A and 1B (the first non-coding exon may be 
alternatively spliced), using Primer3 software 19 (Table 2). PCR reactions were treated with the 
ExoSAP enzyme mix as per manufacturer’s instructions (GE-Amersham). Sequencing was 
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performed for all seven fetal DNAs using Big Dye v3.1 Terminator Cycle Sequencing 
Reactions on an ABI 3130 (Applied Biosystems). Both the sense and antisense strands of the 
PCR-amplified fragments were analyzed with Sequence Analysis software (Applied 
Biosystems).  
Cases 1 and 2 both presented homozygous mutations in the coding sequence of STRA6 
(Figure 1). A homozygous insertion/deletion in exon 2 (c.50_52delACTinsCC) for fetus 1 
causes a frameshift and the appearance of a premature stop codon (p.Asp17Ala fsX55). An 
older brother with isolated bilateral coloboma of the retina and iris was heterozygous for this 
mutation, as were the clinically unaffected parents. Case 2 presented a homozygous single base 
insertion in exon 7 (c.527_528insG) that also predicts a premature stop codon (p.Gly176Gly 
fsX59).  
Case 4 had six intronic variations and one conservative amino acid substitution (Table 
3), all of which were homozygous and documented single nucleotide polymorphisms in the 
general population (dbSNP). Parental samples for fetus 4 were not available for analysis. As 
the fetus was not known to come from a consanguineous background and had a normal 
karyotype, the hypothesis of a small, heterozygous deletion was considered. QMPSF 
(quantitative multiplex PCR of small fluorescent fragments) 20, was undertaken to measure the 
number of genomic STRA6 copies for case 4. The results indicated that this fetus did not 
present a deletion of the STRA6 gene that would explain the observed homozygosity of the 
SNPs (data not shown). 
A single heterozygous variation located in intron 13 (c.1407+32G>A) was observed in 
case 5, that has not been identified to date in dbSNP (Table 3). We screened 260 control 
chromosomes without observing the c.1407+32G>A variation. The only tissue available from 
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fetus 5 for expression analysis was a frozen lung sample. STRA6 transcripts were not observed 
in either total lung RNA extracted from an age-matched fetus affected with an unrelated 
disorder or from the case 5 tissue sample (data not shown). Therefore, the consequence of this 
variation on STRA6 transcription remains to be determined.  
We report homozygous mutations in the STRA6 gene in two fetuses presenting the 
principal features of MWS, including bilateral severe microphthalmia and pulmonary agenesis. 
Both also had bilateral diaphragmatic eventration and one had a cardiac malformation. The 
observation that both fetuses came from consanguineous families and, moreover, that one 
family demonstrated sibling recurrence, had already evoked a recessive model of inheritance 
for MWS 14. By finding the molecular anomaly, it is now possible to affirm that MWS is 
indeed an autosomal recessive disorder that can be ascribed to mutations in the STRA6 gene. 
These two STRA6-mutated fetuses would not have survived postnatally. In both cases, 
the mutations would have led to a truncated protein if translated. Homozygous STRA6 
mutations have also been observed in peri- and postnatal patients from two other families as 
well as in three sporadic cases with a similar phenotypic spectrum 18. However, four missense 
mutations were found to be associated with a severe clinical phenotype while two cases with a 
truncating mutation had milder clinical signs, with no growth retardation or apparent 
pulmonary anomalies. Indeed, one of those patients has survived into his teens. Comparison of 
all reported patients with STRA6 mutations (Table 1) thus demonstrates that there is no 
correlation to date between the nature of a coding mutation and the severity of the phenotype.  
The recent functional study of fifty random missense mutations introduced into bovine 
Stra6 has shown that a few of these are sufficient to prevent cell surface expression and one, 
although allowing protein insertion into the membrane, abrogates vitamin A entry into the cell 
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21. Similar studies will now need to be conducted with documented human mutations in order 
to draw conclusions, but it is probable that phenotypic severity is a result of the reduction in 
perceived retinoic acid (RA) dose within sensitive target tissues, rather than a simple 
distinction between missense and nonsense mutations.  
We also undertook molecular analysis of STRA6 in five other fetuses with pulmonary 
and ocular or cardiac malformations, but no other patent mutations were identified, despite 
some intriguing variations (Table 3). The clinical diversity of patients with STRA6 mutations, 
and the large phenotypic overlap with those who are not mutated, strongly suggests that MWS 
and related syndromes are not only clinically but genetically heterogeneous. 
The only necessary diagnostic criterion predicting the involvement of STRA6, based on 
the patients currently reported here and in the previous study 18, is severe microphthalmia 
(clinical anophthalmia). Microphthalmia with any macroscopically residual presence of the 
ocular globe does not correlate with STRA6 mutations in either series (Table 1). Obviously, 
since many genes have previously been identified in both isolated and syndromic 
microphthalmia, this feature is not sufficient to orient molecular testing. The severe eye 
malformations subsequent to STRA6 mutations are always observed in association with at least 
one other sign, among those of pulmonary defects, congenital diaphragmatic eventration/hernia 
or cardiovascular malformation involving the common aorticopulmonary trunk or pulmonary 
arteries. Furthermore, according to our two MWS cases and descriptions of MWS in the 
literature, pancreatic malformations and IUGR may also be secondary diagnostic criteria. 
Pulmonary defects range from agenesis (this report) to hypoplasia or unilobar lung 
among mutated MWS families, to no obvious lung problems in either member of family 2 
examined by Pasutto et al. 18. Pulmonary and diaphragmatic malformations 
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(eventration/hernia) are not always associated, occurring separately or in combination even 
among members of the same family 18. This observation leads us to conclude that in the 
context of STRA6 mutations, the pulmonary phenotype of mutated patients is a primary 
malformation and not a consequence of diaphragmatic hernia. However, the joint presence of 
clinical anophthalmia and pulmonary and/or diaphragmatic anomalies is still not sufficient to 
guarantee STRA6 involvement, because other cases with bilateral anophthalmia and 
hypoplastic lungs (MWS patients GM23728 and CD50396 from Pasutto et al. 18 and our case 
4) do not present coding sequence mutations (Table 1).  
Cardiovascular involvement is frequent, but inconstant. Case 2 had a ventricular septal 
defect and pulmonary trunk agenesis, while case 1 presented isolated agenesis of the 
pulmonary arteries. Furthermore, STRA6 mutations described by Pasutto et al. also give rise to 
conotruncal or great artery malformations (truncus arteriosus, tetralogy of Fallot, pulmonary 
valve or arterial stenosis, right aortic arch) in at least some family members 18. Other affected 
members with identical mutations had no cardiovascular signs (cf. MWS4-BE). Previously 
described cases of MWS 9, 12 also show a preponderance of pulmonary artery absence, ductus 
arteriosus or ventricular septal defects. 
Fryns syndrome [MIM 229850] has a clinical spectrum that includes diaphragmatic 
hernia and, less frequently, microphthalmia, facial dysmorphy and distal limb anomalies. Fetal 
case 3, presenting with bilateral microphthalmia, pulmonary hypoplasia, diaphragmatic hernia 
and cardiac involvement and cleft palate was diagnosed with Fryns syndrome. Despite the 
implication of the same organ systems as in MWS and absence of a digital phenotype, no 
mutations in the STRA6 coding sequence were found. Patients GM23728 and CD50396 from 
Pasutto et al. 18 also had a similar phenotype (Table 1); the latter was diagnosed with MWS, 
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presented true clinical anophthalmia and had a cleft palate. Palate involvement might therefore 
be suggestive of Fryns syndrome rather than MWS. Phenotypic overlap between these two 
disorders indicates that similar cases diagnosed with Fryns or MWS have either a non-coding 
mutation in STRA6 or involve another gene necessary for the cellular interpretation of RA 
levels. For some authors, animal models of retinoid deficiency also evoke the PAGOD 
syndrome [MIM 202660] (pulmonary tract and pulmonary artery, agonadism, omphalocele, 
diaphragmatic defect, and dextrocardia) which shares features with Fryns and MWS 22. 
 RA, a small lipophilic hormone derived from retinol (vitamin A), is a ligand for nuclear 
receptors (RARα, β and γ), that act in homodimers or in heterodimers with RXR partners to 
bind DNA and regulate the expression of many genes, including the Stra (stimulated by 
retinoic acid) targets 23, 24. The functionally identified Stra genes have different roles and 
structurally unrelated products. For example, Stra1 encodes ephrin B1, a bidirectional, 
membrane-bound signalling molecule highly expressed in the embryonic neural crest 25; Stra7, 
later identified as the evolutionarily conserved transcription factor Gbx2 26, partners with the 
homeobox transcription factor Otx2 in the specification of the isthmic organizer 
(midbrain/hindbrain junction) 27.  
Otx2 was also subsequently identified as a transcriptional target of RA, which leads to 
derepression of Pax6 transcription in the optic cup 28. Interestingly, both OTX2 29 and PAX6 4 
are responsible for human anophthalmias [MIM 610125 and MIM 607108.0005 respectively], 
through heterozygous loss-of-function with incomplete penetrance for the former and 
compound heterozygous loss-of-function engendering a primary anophthalmia for the latter. 
Mutations in EFNB1 (encoding human ephrin B1) induce craniofrontonasal syndrome [MIM 
304110], sometimes in association with congenital diaphragmatic hernia (CDH) 30, 31. We note 
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that CRABP1 (cellular retinoic acid binding protein 1), another transcriptional target and 
effector of cytoplasmic RA levels 32, is located close to reported CDH loci in the long arm of 
chromosome 15. Experimental or teratogenic reductions in RA levels also lead to CDH in both 
animals and humans 33, 34.  
The murine Stra6 gene encodes an integral transmembrane protein that is expressed in 
the developing eye, lung, other endodermal gut derivatives, limbs and somites 23. In addition to 
being stimulated by RA, Stra6 encodes a receptor for soluble retinol binding protein, 
efficiently mediating retinol uptake from the circulation into target cells 21.  
Signaling by RA within the caudal pharyngeal endoderm of the vertebrate embryo is 
critical for the organization of the adjacent aortic arch vessels and heart. Sensitivity of only the 
most posterior aortic arches, which persist in direct continuity with the outflow tract of the 
heart, may be a result of the localized mesodermal production of retinaldehyde dehydrogenase 
2 (Raldh2), a major enzyme for RA synthesis from retinol during development 35. Raldh2-/- 
mice demonstrate 3rd and 4th arch artery malformations with agenesis of the 6th arch 36 in 
addition to cardiac septation defects 37 and partial pancreatic agenesis 38. The variable 
implication of the cardiac outflow tract and vascular derivatives of the embryonic 4th 
(definitive aorta) and 6th (ductus arteriosus and proximal pulmonary artery) aortic arches in our 
patients is consistent with an underlying field defect affecting the perception of RA dose by the 
endoderm.  
Indeed, murine Stra6 is highly expressed in the pharyngeal endoderm and mesenchyme 
along the embryonic gut 23. Our two severely affected, mutated patients had duodenal stenosis 
and pancreatic malformations, in addition to lung agenesis. These organs are among the many 
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derivatives of the embryonic endoderm, produced by localized outpocketings into the 
mesoderm that will consolidate into the definitive structure. 
RA is particularly necessary for normal growth and form of the lung. Fgf10-/- mice 
demonstrate complete lung agenesis 15, 16 while in knockout mice for the appropriate Fgf10-
binding isoform of Fgfr2, the tracheal bifurcation at the origin of the bronchi is absent 17. In 
Raldh2-/- mouse embryos, Fgf10 is no longer expressed in the lung bud and complete agenesis 
results 39. It appears likely that Stra6, expressed among other places in the Raldh2+ bronchial 
mesenchyme of the early lung 23, mediates retinol entry into the mesoderm and a subsequent 
effect on Fgfr2 signaling in the endoderm. Indeed, supplying exogenous RA for short periods 
can partially rescue both Fgf10 expression and lung agenesis, leading to unilobar or unilateral 
right-sided lung development; longer rescue periods lead to better recovery and more subtle 
alveolar malformations 40.  
Stra6 is also expressed at all stages of eye development, within the optic vesicle 
initially and later, within the periocular mesenchyme, the choroid and the optic nerve (and 
forebrain) meninges. Expression in the retinal pigment epithelium persists throughout adult life 
in both mouse and humans 18, 23, indicative of the continued need for RA for ocular function. 
The consistency of clinical anophthalmia in STRA6-mutated patients argues for the need for 
vitamin A uptake to further all stages of eye development following initial optic specification. 
Stra6 transcripts are also detected in several other sites including the forebrain, the 
isthmic organizer and the neurohypophysis. However, no STRA6-mutated patients present 
central nervous system (CNS) malformations or pituitary anomalies, although IUGR or short 
stature may indicate a more subtle effect (Table 1). Murine expression patterns do not always 
suffice to explain clinical outcome 41. Despite the strong, localized brain expression of the RA 
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target Gbx2 (Stra7), its absence in mice gives rise only to posterior branchial arch anomalies 
and cardiac malformations, reminiscent of those observed in patients with STRA6 mutations or 
in Raldh2-/- mice 42. There may also be species-specific differences in the RA sensitivity of the 
developing brain; the clinical spectrum of human vitamin A deficiency syndrome does not 
include the exencephaly observed in mouse models 43. 
In conclusion, STRA6 mutations are responsible for a large spectrum of congenital 
malformations with no current evidence of a genotype-phenotype correlation. Different 
transcriptional targets of RA signaling in humans appear to effect subset phenotypes of those 
observed in more generalized deficiencies 43. MWS is thus part of a growing family of human 
syndromes due to mutations in genes encoding effectors of the powerful developmental 
morphogen, retinoic acid. 
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 Oligonucleotide sequences (5’→3’) 
Exon Forward Reverse 
1a GGGGTGGGTTCCTCTGAT CACCCCAGGTCTCCAAACT 
1b GCTGAAGGCAGGTATGTGTG CCTCTCGTGTCCCCTCCT 
2 AAGCCTCTTTTCACATCTGTAGTG CAGTTGCAACCTCTGCCATC 
3 TGGGTAAAGCCTCAGTGTGA GTTGGACTTGCATCCTGGTT 
4 CAAGCCCTCAAACTCAGACC TGGGGGTCCTGACTAAACCT 
5 CCACCTCCTTGATTTATGGAA GCATCGTTGTAAAGACTGGATG 
6-7 ACCTTCTCATTTTGCCCTTG CTCAAAGGAGGCACTGTGGT 
8 GCAACGGATTCTGGTTCTTG GGAGTAGGGCTGTCTTGGG 
9-10 ACGAATGGGTCGAGGCAG TCTGTGCAAGGGAGGGTAAC 
11 CTTGGGAGGGAGGAGGG GGTTGAGGGCAGGGCTC 
12 CCAGCGTCTCCCCTGTTAG CATAGACCTTGGGTCTCCCC 
13 TGGCAGGGGTTCTGAGG CACAGGACTCCCACTCCTTC 
14 TGGCCCAGAGGAGGATTTAG CCAACTGAGGCCAGTGTCTG 
15-16 AAAGCCCTTGGTTCTGGG ACACCGAAGAAGAGGCGAG 
17 AGGTCTGACACTGACCCTGG GATGCCTTCCTCACTGCTTG 
18 TGGATGCCTCCAGTGTGG AGGGGCACACATCCTTCC 
19 GATCAGGTCTGAGGGCCAG GAGGAGGATGGTAGGCAGG 
 
Table 2. STRA6 oligonucleotides used for sequencing. The annealing 
temperature for PCR was 60°C for all primers. For QMPSF, fluorescent primers 
corresponding to STRA6 exon 13 were used, and MLH1 was chosen as a 
reference (GTAGTCTGTGATCTCCGTTT, 5’; ATGTATGAGGTCCTGTCCT, 
3’). Co-amplification was carried out for 21 cycles, the peaks integrated and 
proportional DNA copy numbers estimated using Genotyper 3.7 software 
(Applied Biosystems). 
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Fetal 
case 
Nucleotide changes versus 
NM_022369 
Predicted effect on 
ORF 
Known SNP 
reference 
Status 
1 c.50_52delACTinsCC p.Asp17Ala fsX55  Homozygous 
2 c.527_528insG  p.Gly176Gly fsX59  Homozygous 
3 none    
4 c.331C>T 
c.406+97A>G  
c.406+111A>G  
c.430+24T>A 
c.431-37C>T  
c.1685-24T>C 
c.1840+50T>C 
p.Leu111Leu  
 
rs11857410 
rs34147822 
rs35255788 
rs971756 
rs971757 
rs12913041 
rs12912578 
Homozygous 
Homozygous 
Homozygous 
Homozygous 
Homozygous 
Homozygous 
Homozygous 
5 c.596+9T>G 
c.1301-43A>C 
c.1416G>A 
 
 
p.Ser472Ser 
rs28541560 
rs351240 
rs351241 
Heterozygous 
Heterozygous 
Heterozygous 
6 c.1166+32G>A   Heterozygous 
7 c.1167-10C>G  rs2277608 Heterozygous 
 
Table 3. Sequence variations in STRA6. 
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Legend 
 
Figure 1. Pedigrees of cases 1 and 2 with markers flanking the STRA6 gene and 
electropherograms. Case 1 (blue arrow) had a homozygous insertion/deletion in exon 2 of STRA6 
(c.50_52delACTinsCC p.AspD17Ala fsX55). Case 2 (yellow arrow) had a homozygous insertion 
in exon 7 (c.527_528insG p.Gly176Gly fsX59).  Markers D15S160, D15S991 and D15S114 
were also homozygous; relatives’ DNA is unavailable for further analysis. wg: weeks gestation 
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